B · Normal
[Shutaishen: Subsidiary product Bometase α for injection will be included in the 2026 National Medical Insurance Catalog] On November 16, Shutaishen (300204.SZ) announced that the company’s subsidiary Jiangsu Beijitai Biotechnology Co., Ltd.’s product Bometase α for injection Mitelase α (Bojia Ning) is included in the "2026 National Medical Insurance Catalog" and is used for the treatment of bleeding in adult patients with congenital hemophilia A or B whose inhibitors of coagulation factor VIII or IX are >5 Bethesda units. The medical insurance classification is Category B. The inclusion of this product in the medical insurance catalog will help reduce patients' medication burden, improve drug accessibility, facilitate product marketing and sales volume, and have a positive effect on long-term business development.
Comments